199 related articles for article (PubMed ID: 12372904)
1. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
2. The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret.
Singh L; Field MJ; Hughes J; Kuo BS; Suman-Chauhan N; Tuladhar BR; Wright DS; Naylor RJ
Eur J Pharmacol; 1997 Feb; 321(2):209-16. PubMed ID: 9063690
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
4. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.
Tattersall FD; Rycroft W; Cumberbatch M; Mason G; Tye S; Williamson DJ; Hale JJ; Mills SG; Finke PE; MacCoss M; Sadowski S; Ber E; Cascieri M; Hill RG; MacIntyre DE; Hargreaves RJ
Neuropharmacology; 2000 Feb; 39(4):652-63. PubMed ID: 10728886
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
[TBL] [Abstract][Full Text] [Related]
6. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
[TBL] [Abstract][Full Text] [Related]
7. A tachykinin NK1 receptor antagonist attenuates the 4 beta-phorbol-12-myristate-13-acetate-induced nociceptive behaviour in the rat.
Tsuchiya M; Sakakibara A; Yamamoto M
Eur J Pharmacol; 2005 Jan; 507(1-3):29-34. PubMed ID: 15659291
[TBL] [Abstract][Full Text] [Related]
8. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
Tattersall FD; Rycroft W; Francis B; Pearce D; Merchant K; MacLeod AM; Ladduwahetty T; Keown L; Swain C; Baker R; Cascieri M; Ber E; Metzger J; MacIntyre DE; Hill RG; Hargreaves RJ
Neuropharmacology; 1996; 35(8):1121-9. PubMed ID: 9121615
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting anti-emetic effect of T-2328, a novel NK(1) antagonist.
Watanabe Y; Okamoto M; Ishii T; Takatsuka S; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jun; 107(2):151-8. PubMed ID: 18544900
[TBL] [Abstract][Full Text] [Related]
10. Antiemetic effect of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-induced acute and delayed emesis in ferrets.
Furukawa TY; Nakayama H; Imazumi K; Yamakuni H; Takeshita K; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2014; 37(2):232-8. PubMed ID: 24492720
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites.
Reed-Hagen AE; Tsuchiya M; Shimada K; Wentland JA; Obach RS
Biopharm Drug Dispos; 1999 Dec; 20(9):429-39. PubMed ID: 10951432
[TBL] [Abstract][Full Text] [Related]
12. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040.
Gardner CJ; Twissell DJ; Dale TJ; Gale JD; Jordan CC; Kilpatrick GJ; Bountra C; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3158-63. PubMed ID: 8719790
[TBL] [Abstract][Full Text] [Related]
13. Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets.
Gonsalves S; Watson J; Ashton C
Eur J Pharmacol; 1996 Jun; 305(1-3):181-5. PubMed ID: 8813551
[TBL] [Abstract][Full Text] [Related]
14. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.
Beattie DT; Beresford IJ; Connor HE; Marshall FH; Hawcock AB; Hagan RM; Bowers J; Birch PJ; Ward P
Br J Pharmacol; 1995 Dec; 116(8):3149-57. PubMed ID: 8719789
[TBL] [Abstract][Full Text] [Related]
15. Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret.
King AG; Sanger GJ
Neurosci Lett; 2005 Mar; 376(1):5-8. PubMed ID: 15694264
[TBL] [Abstract][Full Text] [Related]
16. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
17. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret.
Tattersall FD; Rycroft W; Hargreaves RJ; Hill RG
Eur J Pharmacol; 1993 Nov; 250(1):R5-6. PubMed ID: 8119305
[TBL] [Abstract][Full Text] [Related]
18. [The role of tachykinin NK-1 receptors in emetic action in the area postrema of ferrets].
Saito R; Ariumi H; Kubota H; Nago S; Honda K; Takano Y; Kamiya H
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():209P-214P. PubMed ID: 10629882
[TBL] [Abstract][Full Text] [Related]
19. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
[TBL] [Abstract][Full Text] [Related]
20. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.
Watson JW; Gonsalves SF; Fossa AA; McLean S; Seeger T; Obach S; Andrews PL
Br J Pharmacol; 1995 May; 115(1):84-94. PubMed ID: 7544198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
